- Published on
Approximately 14% of participants in the STEP 1 trial lost less than 5% body weight on semaglutide. Non-response and plateaus have specific causes: inadequate dose escalation, calorie intake above deficit despite reduced appetite, and metabolic adaptation. This article reviews what the evidence shows and what to do.